Examination of Oropharyngeal candidiasis in Infectious patients caused by the Corona Virus Epidemic: A Review Article

In individuals with covid-19, oral candidiasis is apparent, particularly in severe cases, presenting various symptoms such as white lesions on the tongue and oral mucosa. A majority of covid-19 patients who develop oral candidiasis are typically above 50 years of age (Mean age: 53.24 years), often with preexisting conditions like cardiovascular diseases and cancer. The treatment approach for oral candidiasis in covid-19 patients commonly includes the administration of corticosteroids, broad-spectrum antibiotics, and various other pharmaceuticals. The incidence of oral/oropharyngeal candidiasis is higher in men (Mean: 39.8; CI: 10.32-69.28) compared to women (Mean: 31; CI: 9.72-52.38). The initiation of oral candidiasis displays variability among individuals, with symptoms becoming apparent between 1 to 30 days after the onset of covid-19 symptoms. Frequently utilized medications comprise antivirals, antibiotics, anthelmintics, corticosteroids, acetylsalicylic acid, and indomethacin. The use of broad-spectrum antibiotics has been associated with an increased susceptibility to oral candidiasis. Corticosteroids have the potential to disrupt the oral microbiome, thereby fostering the development of oral candidiasis. In the early phases of the pandemic, medications like azithromycin, respiratory fluoroquinolones, cephalosporins, and linezolid were at times prescribed. The onset of oral candidiasis in covid-19 patients can vary, occurring between 1 to 30 days after the onset of covid-19 symptoms. In conclusion, the immune dysfunctions induced by covid-19 significantly impede the body’s ability to combat fungal pathogens such as Candidia albicans, particularly due to inadequate hygiene practices. Understanding the dysregulation of key immune pathways, including Toll-like receptors and the NLRP3 inflammasome, is imperative in elucidating their roles in covid-19 and subsequent fungal infections.